SEC Info℠  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Vagelos P Roy – ‘4’ for 8/11/20 re: Regeneron Pharmaceuticals, Inc.

On:  Thursday, 8/13/20, at 4:02pm ET   ·   For:  8/11/20   ·   Accession #:  1708138-20-94   ·   File #:  0-19034

Previous ‘4’:  ‘4’ on 5/22/20 for 5/20/20   ·   Next:  ‘4’ on 12/11/20 for 12/9/20   ·   Latest:  ‘4’ on 4/5/23 for 4/3/23

Find Words in Filings emoji
 		  in    Show  and   ↓Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 8/13/20  Vagelos P Roy                     4                      1:24K  Regeneron Pharmaceuticals, Inc.   Souza Amanda/FA

Statement of Changes in Beneficial Ownership of Securities by an Insider   —   Form 4   —   SEA’34
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 4           Statement of Changes in Beneficial Ownership of     HTML      3K 
                Securities by an Insider -- edgardoc.xml/3.6


        

This ‘4’ Document is an XML Data File that may be rendered in various formats:

  Form 4    –   Plain Text   –  SEC Website  –  EDGAR System  –    XML Data    –  <?xml?> File
 
 
SEC Info℠ rendering:  Statement of Changes in Beneficial Ownership of Securities by an Insider
 
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
  
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person*
VAGELOS P ROY
(Last)(First)(Middle)
777 OLD SAW MILL RIVER ROAD
(Street)
TARRYTOWNNY10591
(City)(State)(Zip)
2. Issuer Name and Ticker or Trading Symbol
REGENERON PHARMACEUTICALS, INC. [ REGN ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
8/11/20
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock 5/27/20 G (1)V73,100D$0.0234,649D
Common Stock 7/6/20 GV341D$0.0143,559Iby CLAT
Common Stock 8/11/20 S (1) 80D$594.283,572Iby Spouse as Trustee
Common Stock 8/11/20 S (1) 162D$595.69 (2)83,410Iby Spouse as Trustee
Common Stock 8/11/20 S (1) 950D$597.74 (3)82,460Iby Spouse as Trustee
Common Stock 8/11/20 S (1) 843D$598.52 (4)81,617Iby Spouse as Trustee
Common Stock 8/11/20 S (1) 718D$599.37 (5)80,899Iby Spouse as Trustee
Common Stock 8/11/20 S (1) 4,851D$600.3 (6)76,048Iby Spouse as Trustee
Common Stock 8/11/20 S (1) 3,281D$601.42 (7)72,767Iby Spouse as Trustee
Common Stock 8/11/20 S (1) 3,769D$602.66 (8)68,998Iby Spouse as Trustee
Common Stock 8/11/20 S (1) 8,622D$603.54 (9)60,376Iby Spouse as Trustee
Common Stock 8/11/20 S (1) 3,171D$604.35 (10)57,205Iby Spouse as Trustee
Common Stock 8/11/20 S (1) 3,331D$605.41 (11)53,874Iby Spouse as Trustee
Common Stock 8/11/20 S (1) 2,684D$606.51 (12)51,190Iby Spouse as Trustee
Common Stock 8/11/20 S (1) 998D$607.43 (13)50,192Iby Spouse as Trustee
Common Stock 2,209IBy 401(k) Plan
Common Stock 1,203Iby trust for grandch (14)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
(1)  Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).
(2)  Represents volume-weighted average price of sales of 162 shares of Company stock on August 11, 2020 at prices ranging from $595.00 to $595.80. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 11, 2020 at each separate price.
(3)  Represents volume-weighted average price of sales of 950 shares of Company stock on August 11, 2020 at prices ranging from $597.40 to $597.91. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 11, 2020 at each separate price.
(4)  Represents volume-weighted average price of sales of 843 shares of Company stock on August 11, 2020 at prices ranging from $598.04 to $598.85. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 11, 2020 at each separate price.
(5)  Represents volume-weighted average price of sales of 718 shares of Company stock on August 11, 2020 at prices ranging from $599.01 to $599.79. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 11, 2020 at each separate price.
(6)  Represents volume-weighted average price of sales of 4,851 shares of Company stock on August 11, 2020 at prices ranging from $600.00 to $600.96. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 11, 2020 at each separate price.
(7)  Represents volume-weighted average price of sales of 3,281 shares of Company stock on August 11, 2020 at prices ranging from $601.00 to $601.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 11, 2020 at each separate price.
(8)  Represents volume-weighted average price of sales of 3,769 shares of Company stock on August 11, 2020 at prices ranging from $602.05 to $602.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 11, 2020 at each separate price.
(9)  Represents volume-weighted average price of sales of 8,622 shares of Company stock on August 11, 2020 at prices ranging from $603.00 to $603.99. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 11, 2020 at each separate price.
(10)  Represents volume-weighted average price of sales of 3,171 shares of Company stock on August 11, 2020 at prices ranging from $604.01 to $604.89. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 11, 2020 at each separate price.
(11)  Represents volume-weighted average price of sales of 3,331 shares of Company stock on August 11, 2020 at prices ranging from $605.00 to $605.87. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 11, 2020 at each separate price.
(12)  Represents volume-weighted average price of sales of 2,684 shares of Company stock on August 11, 2020 at prices ranging from $606.19 to $606.84. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 11, 2020 at each separate price.
(13)  Represents volume-weighted average price of sales of 998 shares of Company stock on August 11, 2020 at prices ranging from $607.26 to $607.81. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 11, 2020 at each separate price.
(14)  By a trust for the benefit of certain grandchildren of the reporting person, of which the reporting person and/or the spouse of the reporting person is trustee.
/s/**P. Roy Vagelos 8/12/20
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
____________
Transaction Codes:
    G    Bona fide gift.
    S    Open market or private sale of non-derivative or derivative security.

↑Top
Filing Submission 0001708138-20-000094   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)
Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
About — Privacy — Redactions — Help — Sat., Apr. 27, 2:08:07.2am ET